Literature DB >> 1658156

Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans.

L Rasmussen1, C Matkin, R Spaete, C Pachl, T C Merigan.   

Abstract

Antibody to the recombinant gB (rgB) and recombinant gH (rgH) glycoproteins of human cytomegalovirus (CMV) was studied in immunocompetent and immunocompromised humans by immunoprecipitating [35S]methionine-labeled CHO cell lines stably expressing rgB and rgH. Antibody to the rgB precursor was present in greater than 60% of immunocompetent individuals. However rgH antibody was detected in less than 10% of these patients. Antibody to both the rgB and rgH was detected during convalescence in three immunocompetent individuals with symptomatic CMV mononucleosis but to a lesser extent in three others who seroconverted to CMV without symptoms. Antibody to rgB and rgH in heart and heart-and-lung transplant recipients was detected in both primary and recurrent CMV infections but not with the same intensity as in immunocompetent individuals. Selected lots of immune serum globulin, administered prophylactically to bone marrow transplant recipients, were frequently deficient in antibody to rgH but not to rgB.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658156     DOI: 10.1093/infdis/164.5.835

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  An acidic cluster in the cytosolic domain of human cytomegalovirus glycoprotein B is a signal for endocytosis from the plasma membrane.

Authors:  S Tugizov; E Maidji; J Xiao; L Pereira
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Anti-idiotypic mimicry of a neutralizing epitope on the glycoprotein B complex of human cytomegalovirus.

Authors:  E S Tackaberry; J Hamel; Y Larose; B R Brodeur
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

3.  Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites.

Authors:  J A Simpson; J C Chow; J Baker; N Avdalovic; S Yuan; D Au; M S Co; M Vasquez; W J Britt; K L Coelingh
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

Review 4.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

5.  Identification and characterization of the guinea-pig cytomegalovirus glycoprotein H gene.

Authors:  R C Brady; M R Schleiss
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.

Authors:  R Mañez; S Kusne; M Green; K Abu-Elmagd; W Irish; J Reyes; H Furukawa; A Tzakis; J J Fung; S Todo
Journal:  Transplantation       Date:  1995-04-15       Impact factor: 4.939

7.  Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.

Authors:  J L Davignon; P Castanié; J A Yorke; N Gautier; D Clément; C Davrinche
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Prevention of maternal cytomegalovirus infection: current status and future prospects.

Authors:  Jessica L Nyholm; Mark R Schleiss
Journal:  Int J Womens Health       Date:  2010-08-09

9.  Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Authors:  Annalisa Macagno; Nadia L Bernasconi; Fabrizia Vanzetta; Erica Dander; Antonella Sarasini; Maria Grazia Revello; Giuseppe Gerna; Federica Sallusto; Antonio Lanzavecchia
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

10.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.